{"transactions":[{"id":1177656,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-04-04T17:16:46.000Z","date":"2025-02-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":5452,"price":8.07,"value":43997.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on August 1, 2024. The number of shares withheld was determined based on the closing price of the issuer's common stock on February 1, 2025."}],"balance_after":226348,"source":{"system":"sec-edgar","filing":"0001562180-25-003008","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218025003008/primarydocument.xml","form_type":"4"}},{"id":1310747,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2025-01-06T16:59:30.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":95721,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2026 while the optionee provides continuous service to the Issuer."}],"balance_after":95721,"derivative":{"exercise_price":7.86,"expiration_date":"2035-01-02","underlying":"Common Stock","underlying_shares":95721},"source":{"system":"sec-edgar","filing":"0001562180-25-000189","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218025000189/primarydocument.xml","form_type":"4"}},{"id":1310746,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-06T16:59:30.000Z","date":"2025-01-02","kind":"grant","planned":false,"acquired":true,"shares":59347,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2026, January 1, 2027, January 1, 2028\nand January 1, 2029 while the recipient provides continuous service to the Issuer."}],"balance_after":231800,"source":{"system":"sec-edgar","filing":"0001562180-25-000189","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218025000189/primarydocument.xml","form_type":"4"}},{"id":1310745,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2025-01-06T16:59:30.000Z","date":"2025-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":12630,"price":7.73,"value":97629.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022, January 3, 2023 and January 2, 2024. The number of shares withheld was determined on January 2, 2025 based on the closing price of the issuer's common stock on December 31, 2024."}],"balance_after":172453,"source":{"system":"sec-edgar","filing":"0001562180-25-000189","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218025000189/primarydocument.xml","form_type":"4"}},{"id":1440811,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-05T18:38:17.000Z","date":"2024-08-01","kind":"grant","planned":false,"acquired":true,"shares":58867,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of February 1, 2025, August 1, 2025, February 1, 2026 and August 1, 2026 while the recipient provides continuous service to the Issuer."}],"balance_after":185083,"source":{"system":"sec-edgar","filing":"0001562180-24-006013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024006013/primarydocument.xml","form_type":"4"}},{"id":1440810,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-08-05T18:38:17.000Z","date":"2024-06-28","kind":"grant","planned":false,"acquired":true,"shares":1363,"price":9.945,"value":13555.035,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of January 1, 2024 through June 30, 2024. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 28, 2024."}],"balance_after":126216,"source":{"system":"sec-edgar","filing":"0001562180-24-006013","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024006013/primarydocument.xml","form_type":"4"}},{"id":1687899,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2024-01-04T16:22:15.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":61050,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2025 while the optionee provides continuous service to the Issuer."}],"balance_after":61050,"derivative":{"exercise_price":18.34,"expiration_date":"2034-01-02","underlying":"Common Stock","underlying_shares":61050},"source":{"system":"sec-edgar","filing":"0001562180-24-000249","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024000249/primarydocument.xml","form_type":"4"}},{"id":1687898,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:22:15.000Z","date":"2024-01-02","kind":"grant","planned":false,"acquired":true,"shares":38462,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F6","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2025, January 1, 2026, January 1, 2027 and January 1, 2028 while the recipient provides continuous service to the Issuer."}],"balance_after":124853,"source":{"system":"sec-edgar","filing":"0001562180-24-000249","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024000249/primarydocument.xml","form_type":"4"}},{"id":1687897,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:22:15.000Z","date":"2024-01-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":8410,"price":17.95,"value":150959.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021, January 3, 2022 and January 3, 2023. The number of shares withheld was determined on January 2, 2024 based on the closing price of the Issuer's common stock on December 29, 2023."}],"balance_after":86391,"source":{"system":"sec-edgar","filing":"0001562180-24-000249","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024000249/primarydocument.xml","form_type":"4"}},{"id":1687896,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:22:15.000Z","date":"2023-06-30","kind":"grant","planned":false,"acquired":true,"shares":1123,"price":16.9915,"value":19081.4545,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2023 through June 30, 2023. This\ntransaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2023."}],"balance_after":94801,"source":{"system":"sec-edgar","filing":"0001562180-24-000249","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024000249/primarydocument.xml","form_type":"4"}},{"id":1687895,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2024-01-04T16:22:15.000Z","date":"2022-06-30","kind":"grant","planned":false,"acquired":true,"shares":728,"price":20.995,"value":15284.36,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of January 1, 2022 through June 30, 2022. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2022."}],"balance_after":93678,"source":{"system":"sec-edgar","filing":"0001562180-24-000249","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218024000249/primarydocument.xml","form_type":"4"}},{"id":2062795,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Options (Right to buy)","published_at":"2023-01-05T16:06:16.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":52986,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer."}],"balance_after":52986,"derivative":{"exercise_price":22.25,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":52986},"source":{"system":"sec-edgar","filing":"0001562180-23-000220","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218023000220/primarydocument.xml","form_type":"4"}},{"id":2062794,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-05T16:06:16.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":65930,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer."}],"balance_after":92950,"source":{"system":"sec-edgar","filing":"0001562180-23-000220","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218023000220/primarydocument.xml","form_type":"4"}},{"id":2062793,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2023-01-05T16:06:16.000Z","date":"2023-01-03","kind":"tax_withholding","acquired":false,"shares":2058,"price":22.68,"value":46675.44,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022."}],"balance_after":27020,"source":{"system":"sec-edgar","filing":"0001562180-23-000220","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218023000220/primarydocument.xml","form_type":"4"}},{"id":2449475,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-01-04T21:04:25.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":51100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2023 while the optionee provides continuous service to the Issuer."}],"balance_after":51100,"derivative":{"exercise_price":34.31,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":51100},"source":{"system":"sec-edgar","filing":"0001562180-22-000156","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218022000156/primarydocument.xml","form_type":"4"}},{"id":2449474,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T21:04:25.000Z","date":"2022-01-03","kind":"grant","acquired":true,"shares":10700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2023, January 1, 2024, January 1, 2025 and January 1, 2026 while the recipient provides continuous service to the Issuer."}],"balance_after":29078,"source":{"system":"sec-edgar","filing":"0001562180-22-000156","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218022000156/primarydocument.xml","form_type":"4"}},{"id":2449473,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T21:04:25.000Z","date":"2022-01-01","kind":"tax_withholding","acquired":false,"shares":1221,"price":32.7,"value":39926.7,"ownership":{"direct":true},"balance_after":18378,"source":{"system":"sec-edgar","filing":"0001562180-22-000156","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218022000156/primarydocument.xml","form_type":"4"}},{"id":2449472,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T21:04:25.000Z","date":"2021-12-31","kind":"grant","acquired":true,"shares":1,"price":27.795,"value":27.795,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of July 1, 2021 through December 31, 2021. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2021."}],"balance_after":19599,"source":{"system":"sec-edgar","filing":"0001562180-22-000156","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218022000156/primarydocument.xml","form_type":"4"}},{"id":2449471,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2022-01-04T21:04:25.000Z","date":"2021-06-30","kind":"grant","acquired":true,"shares":555,"price":33.0225,"value":18327.4875,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of January 1, 2021 through June 30, 2021. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2021."}],"balance_after":19598,"source":{"system":"sec-edgar","filing":"0001562180-22-000156","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218022000156/primarydocument.xml","form_type":"4"}},{"id":2915915,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-01-06T08:53:15.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":52500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 4, 2022 while the optionee provides continuous service to the Issuer."}],"balance_after":52500,"derivative":{"exercise_price":44.97,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":52500},"source":{"system":"sec-edgar","filing":"0001562180-21-000141","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218021000141/primarydocument.xml","form_type":"4"}},{"id":2915914,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T08:53:15.000Z","date":"2021-01-04","kind":"grant","acquired":true,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2022, January 1, 2023, January 1, 2024 and January 1, 2025 while the recipient provides continuous service to the Issuer."}],"balance_after":19043,"source":{"system":"sec-edgar","filing":"0001562180-21-000141","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218021000141/primarydocument.xml","form_type":"4"}},{"id":2915913,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T08:53:15.000Z","date":"2020-06-30","kind":"grant","acquired":true,"shares":641,"price":31.3055,"value":20066.8255,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F3","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the ESPP for the ESPP purchase period of January 1, 2020 through June 30, 2020. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on June 30, 2020."}],"balance_after":7443,"source":{"system":"sec-edgar","filing":"0001562180-21-000141","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218021000141/primarydocument.xml","form_type":"4"}},{"id":2915912,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2021-01-06T08:53:15.000Z","date":"2019-12-31","kind":"grant","acquired":true,"shares":302,"price":34.8245,"value":10516.999,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the REGENXBIO Inc. Employee Stock Purchase Plan (\"ESPP\") for the ESPP purchase period of July 1, 2019 through December 31, 2019. This transaction is exempt under Rule 16b-3(c)."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on December 31, 2019."}],"balance_after":6802,"source":{"system":"sec-edgar","filing":"0001562180-21-000141","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218021000141/primarydocument.xml","form_type":"4"}},{"id":3318617,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2020-01-06T16:23:55.000Z","date":"2020-01-02","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer."}],"balance_after":48000,"derivative":{"exercise_price":38.99,"expiration_date":"2030-01-02","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001562180-20-000218","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218020000218/primarydocument.xml","form_type":"4"}},{"id":3554042,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-04-17T16:19:41.000Z","date":"2019-04-15","kind":"exercise","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer."}],"balance_after":71500,"derivative":{"exercise_price":20.35,"expiration_date":"2027-03-26","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001562180-19-002295","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019002295/primarydocument.xml","form_type":"4"}},{"id":3554041,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-04-17T16:19:41.000Z","date":"2019-04-15","kind":"sale","acquired":false,"shares":1000,"price":53.09,"value":53090.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $52.94 to $53.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001562180-19-002295","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019002295/primarydocument.xml","form_type":"4"}},{"id":3554040,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-04-17T16:19:41.000Z","date":"2019-04-15","kind":"sale","acquired":false,"shares":1000,"price":52.23,"value":52230.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $51.88 to $52.71. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":7500,"source":{"system":"sec-edgar","filing":"0001562180-19-002295","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019002295/primarydocument.xml","form_type":"4"}},{"id":3554039,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-04-17T16:19:41.000Z","date":"2019-04-15","kind":"exercise","acquired":true,"shares":2000,"price":20.35,"value":40700.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":8500,"source":{"system":"sec-edgar","filing":"0001562180-19-002295","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019002295/primarydocument.xml","form_type":"4"}},{"id":3595609,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-03-14T16:17:37.000Z","date":"2019-03-12","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer."}],"balance_after":73500,"derivative":{"exercise_price":20.35,"expiration_date":"2027-03-26","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001562180-19-001906","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019001906/primarydocument.xml","form_type":"4"}},{"id":3595608,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2019-03-14T16:17:37.000Z","date":"2019-03-12","kind":"exercise","acquired":true,"shares":5000,"price":20.35,"value":101750.0,"ownership":{"direct":true},"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001562180-19-001906","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019001906/primarydocument.xml","form_type":"4"}},{"id":3702055,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2019-01-07T16:24:38.000Z","date":"2019-01-03","kind":"grant","acquired":true,"shares":48000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer."}],"balance_after":48000,"derivative":{"exercise_price":40.82,"expiration_date":"2029-01-03","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001562180-19-000220","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218019000220/primarydocument.xml","form_type":"4"}},{"id":3743846,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-12-04T16:19:12.000Z","date":"2018-11-30","kind":"exercise","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer."}],"balance_after":78500,"derivative":{"exercise_price":20.35,"expiration_date":"2027-03-26","underlying":"Common Stock","underlying_shares":1500},"source":{"system":"sec-edgar","filing":"0001562180-18-004807","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004807/primarydocument.xml","form_type":"4"}},{"id":3743845,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-12-04T16:19:12.000Z","date":"2018-11-30","kind":"exercise","acquired":true,"shares":1500,"price":20.35,"value":30525.0,"ownership":{"direct":true},"balance_after":1500,"source":{"system":"sec-edgar","filing":"0001562180-18-004807","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004807/primarydocument.xml","form_type":"4"}},{"id":3793609,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The previously granted option, representing a right to purchase a total of 100,000 shares, became exercisable as follows: 25% of the shares subject to this option vested on March 27, 2018, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer."}],"balance_after":80000,"derivative":{"exercise_price":20.35,"expiration_date":"2027-03-26","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":3793608,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"sale","acquired":false,"shares":216,"price":65.6,"value":14169.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This transaction was executed in multiple trades at prices ranging from $65.40 to $65.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":3793607,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"sale","acquired":false,"shares":4000,"price":64.78,"value":259120.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $64.36 to $65.33. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":216,"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":3793606,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"sale","acquired":false,"shares":12284,"price":63.73,"value":782859.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $63.35 to $64.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":4216,"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":3793605,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"sale","acquired":false,"shares":3500,"price":62.79,"value":219765.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $62.31 to $63.30. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":16500,"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":3793604,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Common Stock","published_at":"2018-10-10T16:20:48.000Z","date":"2018-10-08","kind":"exercise","acquired":true,"shares":20000,"price":20.35,"value":407000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan."}],"balance_after":20000,"source":{"system":"sec-edgar","filing":"0001562180-18-004207","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018004207/primarydocument.xml","form_type":"4"}},{"id":4105650,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2018-01-05T16:49:00.000Z","date":"2018-01-03","kind":"grant","acquired":true,"shares":41250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2019 while the optionee provides continuous service to the Issuer."}],"balance_after":41250,"derivative":{"exercise_price":35.8,"expiration_date":"2028-01-03","underlying":"Common Stock","underlying_shares":41250},"source":{"system":"sec-edgar","filing":"0001562180-18-000240","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000156218018000240/primarydocument.xml","form_type":"4"}},{"id":4369423,"issuer":{"id":2211,"kind":"organization","name":"REGENXBIO Inc.","symbol":"RGNX"},"owners":[{"id":81049,"kind":"person","name":"Danos Olivier","position":1,"cik":"0001701180","reported_name":"Danos Olivier","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Scientific Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2017-03-29T17:15:38.000Z","date":"2017-03-27","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following 3/27/2018 while the optionee provides continuous service to the Issuer."}],"balance_after":100000,"derivative":{"exercise_price":20.35,"expiration_date":"2027-03-26","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000899243-17-008828","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701180/000089924317008828/doc4.xml","form_type":"4"}}]}